Study investigates Curculiginis Rhizoma (CR) mixed with cisplatin to combat chemoresistance in NSCLC. Results show potential to enhance drug sensitivity by targeting ABC transporters. Crucial for improving chemotherapy outcomes in lung cancer.
Two plant-derived products, BJOE and ADI, show promise in treating CRC with limited options, allowing a patient with resectable lung metastases to achieve >5 years progression-free survival. More research needed, but offers hope for future treatments.
Piperine from black pepper shows potential as an anticancer agent for head and neck cancer. It inhibits cell growth, triggers apoptosis, and reduces inflammation and migration. It may be effective in regulating signaling pathways associated with cancer development.
Study identified active components of Houttuynia cordata for CRC treatment. Quercetin and kaempferol target genes IL1B, MMP9, CXCL8, and IL6, inhibiting cell growth and promoting apoptosis. Potential for immunomodulation in CRC treatment.
Okra compounds like Quercetin 3-gentiobioside show potential as Aromatase inhibitors for estrogen receptor-positive breast cancer, with superior binding affinity and stability. Promising candidates for further preclinical studies.
SDW components target 88 genes in lung cancer treatment, inhibiting cell proliferation via P I3K/Akt and MEK/ERK pathways. SDW may regulate apoptosis and proliferation in lung cancer therapy. Valuable insights into molecular mechanisms provided through network pharmacology, molecular docking, and experimental validation.
Study tested methanolic extract for anticancer properties on lung cancer cells. Implications for potential cancer treatment.